Señalización PI3K / Akt / mTOR
Los inhibidores de la señalización PI3K/Akt/mTOR son compuestos que se dirigen a las vías de la fosfoinositida 3-cinasa (PI3K), la cinasa Akt y el blanco de la rapamicina en mamíferos (mTOR). Estas vías son reguladores críticos del crecimiento celular, la supervivencia, el metabolismo y la autofagia, lo que las convierte en objetivos clave en la investigación del cáncer y los trastornos metabólicos. Inhibir estas vías puede ayudar a controlar el crecimiento y la proliferación tumoral, ofreciendo potenciales estrategias terapéuticas para varios tipos de cáncer y otras enfermedades caracterizadas por una señalización celular desregulada. En CymitQuimica, ofrecemos una amplia selección de inhibidores de alta calidad de PI3K/Akt/mTOR para apoyar su investigación en oncología, señalización celular y enfermedades metabólicas.
Subcategorías de "Señalización PI3K / Akt / mTOR"
- AMPK(168 productos)
- ATM / ATR(72 productos)
- ADN-PK(49 productos)
- EGFR(595 productos)
- MELK(7 productos)
- PDK(9 productos)
- PI3K(236 productos)
- Quinasa S6(8 productos)
- gsk-3(110 productos)
- mTOR(162 productos)
Mostrar 2 subcategorías más
Se han encontrado 1026 productos de "Señalización PI3K / Akt / mTOR"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
MS9427 TFA
MS9427 TFA: PROTAC EGFR degrader, Kd 7.1 nM (WT), 4.3 nM (L858R), targets mutant EGFR, inhibits NSCLC cell growth, for cancer research.Fórmula:C50H59ClF4N8O14Forma y color:SolidPeso molecular:1107.5GSK251
CAS:GSK251 is a novel, orally bioavailable inhibitor of PI3Kδ, exhibiting high potency and selectivity, with a unique binding mode.Fórmula:C29H37FN6O4SPureza:99.8%Forma y color:SolidPeso molecular:584.71EGFR kinase inhibitor 2
EGFR kinase inhibitor 2 (compound A-7) is a potent EGFR inhibitor targeting the mutations EGFRL858R/T790M/C797S and EGFRDel19/T790M/C797S. This compound shows potential in addressing acquired resistance in the treatment of non-small cell lung cancer.Fórmula:C39H40N6O5Peso molecular:672.30602DSPE-PEG1000-GE11
<p>DSPE-PEG1000-GE11 is a PEG compound made up of DSPE and an EGFR-targeting peptide (GE11). GE11 is applicable for cancer cells overexpressing EGFR. DSPE-PEG1000-GE11 serves a role in drug delivery.</p>Forma y color:Odour SolidDalmitamig
Dalmitamig is a humanized IgG4κ antibody targeting EGFR/CD28, with HumanIgG4(S228P) kappa as its corresponding isotype control.Forma y color:Odour LiquidPX-866-17OH
CAS:PX-866-17OH can be used in related research in the field of life sciences. Its product number is T36312 and CAS number is 1012327-63-7.Fórmula:C29H37NO8Forma y color:SolidPeso molecular:527.61MELK-8a Dihydrochloride
<p>MELK-8a Dihydrochloride is a useful organic compound for research related to life sciences and the catalog number is T35342.</p>Pureza:98%Forma y color:SolidHER2-IN-20
<p>HER2-IN-20 (compound 32) is a potent and selective inhibitor of HER2WT and HER2YVMA, with IC50 values of 49 and 42 nM, respectively. It holds potential for research in non-small cell lung cancer (NSCLC).</p>Fórmula:C30H27ClFN7O2Peso molecular:571.18988Duvelisib (R enantiomer) hydrochloride
Duvelisib (R enantiomer) hydrochloride (INK1197 R enantiomer HCl) is a PI3K inhibitor.Fórmula:C22H18Cl2N6OPureza:99.86% - 99.88%Forma y color:SoildPeso molecular:453.32Varlitinib
CAS:Varlitinib (ASLAN001) is a potent, reversible, small molecule pan-EGFR inhibitor with IC50s of 7, 2, 4 nM for HER1, HER2 and HER4, respectively.Fórmula:C22H19ClN6O2SPureza:99.7%Forma y color:SolidPeso molecular:466.94JYQ-164
<p>JYQ-164 is a small molecule inhibitor targeting human Parkinson's disease protein 7 (PARK7/DJ-1). It functions by covalently and selectively targeting the critical residue Cys106 of PARK7, exhibiting an IC50 of 21 nM. JYQ-164 demonstrates five times greater inhibitory potency against PARK7 compared to the previously reported inhibitor, JYQ-88. It is applicable for research in Parkinson's disease and cancer.</p>Fórmula:C23H26N6O5S2Peso molecular:530.14061PRMT5/EGFR-IN-1
PRMT5/EGFR-IN-1 (Compound 10p) is an orally active dual inhibitor targeting PRMT5 and EGFR, with IC50 values of 15.47 μM and 19.31 μM, respectively. It demonstrates antiproliferative activity against the A549, MCF7, HeLa, and MDA-MB-231 cell lines. This compound also exhibits favorable pharmacokinetic (PK) and pharmacodynamic (PD) properties in vivo and significantly inhibits the growth of MCF7 orthotopic xenograft tumors.Fórmula:C27H22F6N2O2Peso molecular:520.15855GSK-3β inhibitor 24
GSK-3β inhibitor24 (Compound 41) is a potent GSK-3β inhibitor with an IC50 of 0.22 nM. It increases GSK-3β phosphorylation at the Ser9 site in a dose-dependent manner and inhibits tau protein hyperphosphorylation by reducing the abundance of p-tau-Ser396. The compound upregulates β-catenin and neurogenesis-related markers (GAP43 and MAP-2), demonstrating significant anti-Alzheimer's disease (AD) activity.Fórmula:C26H18N4O3Forma y color:SolidPeso molecular:434.446PROTAC EGFR degrader 10
CAS:PROTAC EGF Rdegrader 10 (Compound B56) is a PROTAC degrader targeting the epidermal growth factor receptor (EGFR) with a DC50 of less than 100 nM. It binds to CRBN-DDB1 with a Ki of 37 nM and degrades EGFR, focal adhesion kinase (FAK), and RSK1, inhibiting the proliferation of BaF3 wild-type and EGFR mutants with an IC50 of less than 150 nM.Fórmula:C49H65ClN10O7SForma y color:SolidPeso molecular:973.62EGFR WT/T790M/L858R-IN-1
EGFRWT/T790M/L858R-IN-1 (compound 10d) is a potent inhibitor of EGFR, demonstrating IC50 values of 0.097, 0.280, and 0.051 μM for EGFRWT, EGFRT790M, and EGFRL858R, respectively. This compound can be utilized in cancer research.Fórmula:C26H25Cl3N2O3Peso molecular:518.09308MS39N
CAS:<p>MS39N (compound 27) serves as the negative control for MS39, capable of binding to EGFR without causing its degradation.</p>Fórmula:C55H71ClFN9O7SPeso molecular:1056.73EGFR-IN-95
<p>EGFR-IN-95 is a derivative of 2,4-diaminonicotinamide. It effectively inhibits the activity of EGFRdel19/T790M/C797S and L858R/T790M/C797S.</p>Fórmula:C23H28F2N8O3SPeso molecular:534.19731ZM 449829
CAS:ZM 449829: Selective JAK3 inhibitor, binds to ATP site. pIC50: 6.8 for JAK3, others < 5.0.Fórmula:C13H10OPureza:98%Forma y color:SolidPeso molecular:182.222PI3Kδ-IN-12
PI3Kδ-IN-12 (compound 13), a PI3Kδ inhibitor with a pIC50 of 5.8, exhibits differential binding affinities with pKi values of 8.0 for PI3Kδ, 6.5 for PI3Kγ, 6.4Fórmula:C20H15Cl2N5O3Pureza:98%Forma y color:SolidPeso molecular:444.27PROTAC EGFR degrader 11
CAS:<p>PROTAC EGFR degrader 11 (Compound B71) is a PROTAC degrader targeting the epidermal growth factor receptor (EGFR), with a DC50 of less than 100 nM. It binds to CRBN-DDB1 with a Ki of 36 nM. This compound effectively degrades EGFR, focal adhesion kinase (FAK), and RSK1, and inhibits the proliferation of BaF3 wild-type and EGFR mutant cells, exhibiting an IC50 of less than 100 nM.</p>Fórmula:C49H64ClFN10O7SForma y color:SolidPeso molecular:991.61EGFR T790M/L858R-IN-6
CAS:<p>EGFR T790M/L858R-IN-6 (compound 53), classified as a pyrimidine compound, serves as an effective inhibitor of EGFR T790M/L858R, demonstrating 90.88% inhibition of enzyme activity at a concentration of 0.05 μM [1].</p>Fórmula:C27H27N7O2Forma y color:SolidPeso molecular:481.55EGFR/VEGFR2-IN-5
EGFR/VEGFR2-IN-5 (Compound 14) is an orally active dual inhibitor of EGFR and VEGFR2, exhibiting an IC50 value of 1.15 µM for VEGFR2 and 0.28 µM for EGFRT790M. This compound demonstrates significant anticancer activity.Fórmula:C17H15N7O5SForma y color:SolidPeso molecular:429.41EGFR-IN-42
EGFR-IN-42 (17b) is a potent EGFR inhibitor with nanomolar efficacy, merging tamoxifen/endoxifen and gefitinib, exhibiting enhanced anti-cancer action.Fórmula:C49H53ClFN5O5Forma y color:SolidPeso molecular:846.43Thioether-cyclized helix B peptide, CHBP TFA
Thioether-cyclized helix B peptide, CHBP (TFA), is the trifluoroacetic (TFA) salt of CHBP.Fórmula:C56H93N19O22S·xC2HF3O2Pureza:98%Forma y color:SolidPeso molecular:1416.52 (free base)STX-478
CAS:STX-478 (compound 80), an orally administered, CNS-penetrant allosteric mutant-selective PI3Kα inhibitor, demonstrates significant and sustained tumorFórmula:C16H12F5N5O2Pureza:98.31% - 99.78%Forma y color:SolidPeso molecular:401.29PROTAC EGFR degrader 2
Potent PROTAC EGFR degrader 2; IC50: 4.0 nM, DC50: 36.51 nM; inhibits cell growth; for NTR-responsive synthesis.Fórmula:C58H72ClFN12O8SForma y color:SolidPeso molecular:1151.78KR-27370
KR-27370 (compound 7f) is an antiviral agent and a selective PI4KIIIβ/PI4KIIIα inhibitor, with IC50 values of 3.1 nM and 15.8 nM, respectively. It exhibits inhibitory activity against human rhinovirus (hRV), Coxsackievirus, and other enteroviruses.Fórmula:C27H27N3O6S2Peso molecular:553.13413FDA-Approved Kinase Inhibitor Library
<p>A unique collection of 263 kinase inhibitors/regulators for specific targeting of kinases, ready for high-throughput screening and high-content screening.</p>Forma y color:LiquidBMS-599626 2HCL(714971-09-2 Free base)
CAS:<p>BMS-599626 2HCL (AC480 2HCl) is a BMS-599626 derivative.</p>Fórmula:C27H29Cl2FN8O3Pureza:99.11%Forma y color:Odour SolidPeso molecular:603.47PI3Kγ inhibitor 5
CAS:PI3Kγ inhibitor 5 is a potent inhibitor of phosphoinositide 3-kinase γ (PI3Kγ), exhibiting an exceptional IC50 value of 34 nM.Fórmula:C28H32F2N6O4Forma y color:SolidPeso molecular:554.599Kinase Inhibitor Library
<p>A unique collection of 2720 kinase inhibitors/regulators for high throughput screening and high content screening for drug discovery in kinase related diseases;</p>Forma y color:Odour SolidEP26
EP26 is an orally active and potent inhibitor of EGFR and PD-L1, with IC50 values of 48.6 nM and 1.77 µM, respectively. It reduces the protein expression of p-EGFR and induces cell cycle arrest at the G0/G1 phase. EP26 shows potential for glioblastoma research.Fórmula:C42H42ClFN4O5Peso molecular:736.28278FRF-06-057
FRF-06-057 is an allosteric ATP EGFR inhibitor targeting both wild-type and mutant EGFR, with IC50 values of 17 nM (LR/TM), 29 nM (LR/TM/CS), 220 nM (LR), and >1000 nM (WT).Fórmula:C19H13N3O3SForma y color:SolidPeso molecular:363.39MS9427
CAS:<p>MS9427: PROTAC EGFR degrader, 7.1 nM (WT), 4.3 nM (L858R); targets mutant via UPS and autophagy; inhibits NSCLC cell growth; anticancer research.</p>Fórmula:C48H58ClFN8O12Forma y color:SolidPeso molecular:993.474-Epidoxycycline
CAS:<p>4-Epidoxycycline is a hepatic metabolite of the antibiotic doxycycline and lacks antibiotic properties in mice. In both in vitro assays and in vivo mouse models, 4-Epidoxycycline regulates HER2 gene expression similarly to doxycycline and exhibits comparable efficacy in tumor tissues, achieving over 95% tumor regression rates.</p>Fórmula:C22H24N2O8Forma y color:SolidPeso molecular:444.44HDS 029
CAS:<p>HDS 029 has a wide range of applications in life science related research.</p>Fórmula:C17H11ClFN5OForma y color:SolidPeso molecular:355.76Simotinib hydrochloride
CAS:Simotinib hydrochloride: selective oral EGFR inhibitor, IC50 19.9 nM, potent anticancer agent.Fórmula:C25H27Cl2FN4O4Forma y color:SolidPeso molecular:537.41DP-C-4
DP-C-4 is a Cereblon-based dual PROTAC for simultaneous degradation of EGFR and PARP[1].Forma y color:LiquidMulti-target kinase inhibitor 4
<p>Multi-target kinase inhibitor 4 (Compound 2) is a PI3K/DNA-PK inhibitor and a potent chemosensitizer that enhances the number of DNA double-strand breaks induced by Doxorubicin. It serves as an effective multidrug resistance (MDR) inhibitor, demonstrating inhibitory activity against P-glycoprotein (P-gp) mediated drug efflux. Multi-target kinase inhibitor 4 can be encapsulated in PEG-coated lipid nanoparticles.</p>Forma y color:Odour SolidEGFR-IN-140
EGFR-IN-140 (Compound 31) is an inhibitor of EGFR, effectively targeting both wild-type EGFR and the EGFRL858R/T790M/C797S mutant, with Ki values of 0.95 nM and 2.1 nM, respectively. Additionally, it inhibits EGFRdel19/T790M/C797S in Ba/F3 cells with an IC50 of 56.9 nM and demonstrates antitumor activity in mouse models.Fórmula:C27H37FN8O2Forma y color:SolidPeso molecular:524.633TX2-120-1
CAS:TX2-120-1 possesses the ability to bind with Her3, exhibiting an IC50 of 56 nM for Her3. It can be utilized in the synthesis of TX2-121-1.Fórmula:C26H27N7O2Forma y color:SolidPeso molecular:469.54SJF 1521
CAS:<p>SJF 1521 is an EGFR degrader belonging to the PROTAC class that selectively degrades EGFR while preserving HER2.</p>Fórmula:C57H61ClFN7O9SPureza:99.20%Forma y color:SolidPeso molecular:1074.65PI3-Kinase α Inhibitor 2 (hydrochloride)
CAS:PI3-Kinase α Inhibitor 2 (hydrochloride) is a PI3-Kinase α inhibitor.Fórmula:C16H17Cl2N3O2SForma y color:SolidPeso molecular:386.3740 Y-P acetate
740 Y-P acetate (740YPDGFR acetate) is a potent and cell-permeable PI3K activator.740 Y-P acetate tends to bind to GST fusion proteins containing the N- and C-Fórmula:C143H226N43O41PS3Pureza:99.92%Forma y color:SoildPeso molecular:3330.79IC 86621
CAS:<p>IC 86621: DNA-PK ATP-competitive inhibitor, IC50 120 nM, enhances DSB antitumor effects, EC50 68 µM for repair.</p>Fórmula:C12H15NO3Pureza:99.68%Forma y color:SolidPeso molecular:221.25HL-8
CAS:HL-8, a PROTAC targeting PI3K, degrades it fully at 10 μM in 8h, useful in cancer research.Fórmula:C57H59F2N11O9S2Forma y color:SolidPeso molecular:1144.27GSK3β Inhibitor XI
CAS:GSK3β Inhibitor XI has GSK3β inhibitory effect.Fórmula:C18H15N5O3Forma y color:SolidPeso molecular:349.35(R)-VX-984
CAS:(R)-VX-984 ((R)-M9831) is the (R)-enantiomer of VX-984. VX-984 is a potent inhibitor of DNA-PK.Fórmula:C23H21D2N7OPureza:98%Forma y color:SolidPeso molecular:415.49GSK2292767 FA
<p>GSK2292767 FA: potent PI3Kδ inhibitor, pIC50=10.1, 500x selectivity, for respiratory research.</p>Fórmula:C25H30N6O7SPureza:99.52%Forma y color:SoildPeso molecular:558.61Umbralisib R-enantiomer
CAS:<p>Umbralisib R-enantiomer (RP5264 R-enantiomer) is a delta inhibitor of PI3K and a less active enantiomer of TGR-1202.</p>Fórmula:C31H24F3N5O3Pureza:97.34%Forma y color:SolidPeso molecular:571.55AG-1478 hydrochloride
CAS:AG1478 HCl is an epidermal growth factor receptor protein inhibitor.Fórmula:C16H15Cl2N3O2Forma y color:SolidPeso molecular:352.21mTOR inhibitor 9e
CAS:<p>mTOR inhibitor 9e is a selective mTOR inhibitor with IC50 of 0.68nM and 1359nM for mTOR and PI3Kα, respectively.</p>Fórmula:C22H23N5O2SPureza:98.84%Forma y color:SoildPeso molecular:421.52Phosphatidylinositol 4,5-bisphosphate
CAS:Phosphatidylinositol 4,5-bisphosphate, a cell membrane phospholipid, is a PLC and PI3K substrate and a messenger.Fórmula:C47H85O19P3Forma y color:SolidPeso molecular:1047.09Dacomitinib metabolite M2
CAS:Dacomitinib metabolite M2 is also known as Dacomitinib cysteine conjugate. Dacomitinib inhibits both the wild-type (WT) EGFR and EGFR T790M.Fórmula:C27H32ClFN6O4SForma y color:SolidPeso molecular:591.1Necitumumab
CAS:Necitumumab (IMC-11F8) is a human monoclonal antibody against EGFR, an anti-angiogenic agent used in the treatment of advanced non-small cell lung cancer.Pureza:97.9% (SDS-PAGE); 99.1% (SEC-HPLC) - 97.9% (SDS-PAGE); 99.1% (SEC-HPLC)Forma y color:LiquidPeso molecular:145.5 kDaJBJ-09-063 TFA
JBJ-09-063 TFA, an EGFR inhibitor selective for EGFR mutations, IC50s: 0.147-0.396 nM, blocks EGFR/Akt/ERK signaling, for EGFR-mutant lung cancer research.Fórmula:C33H30F4N4O5SForma y color:SolidPeso molecular:670.67DSPE-PEG5000-GE11
DSPE-PEG5000-GE11 is a PEG compound composed of DSPE and the EGFR-targeting peptide (GE11). GE11 is applicable for cancer cells with EGFR overexpression. DSPE-PEG5000-GE11 is utilized in drug delivery.Forma y color:Odour SolidPROTAC PI3K/110β degrader-1
CAS:<p>PROTACPI3K/110β degrader-1 (J-9) acts as a PROTAC degrader specifically targeting PI3K/110β.</p>Fórmula:C51H65N9O9SForma y color:SolidPeso molecular:980.18AZ14240475
AZ14240475 is a potent, selective, brain-penetrant inhibitor of EGFREx20Ins mutants (EGFREx20Ins mutants) with a pIC50 of 7.6, playing a significant role in cancer research.Fórmula:C23H15ClF2N6O2Forma y color:SolidPeso molecular:480.854ARUK2001607
CAS:ARUK2001607 selectively inhibits PI5P4Kγ (Kd=7.1 nM) with high selectivity over 150+ kinases.Fórmula:C14H13N3O2S2Pureza:99.75%Forma y color:SoildPeso molecular:319.40BMS-599626
CAS:BMS-599626 (AC480) has been used in trials studying the treatment of Cancer, Metastases, and HER2 or EGFR Expressing Advanced Solid Malignancies.Fórmula:C27H27FN8O3Pureza:98.73%Forma y color:SolidPeso molecular:530.55HER2-IN-14
CAS:HER2-IN-14 (Compound 34) is a potent inhibitor of HER2, achieving an inhibitory concentration (IC50) of 18 nM.Fórmula:C26H23ClF2N8O3Forma y color:SolidPeso molecular:568.96Amdizalisib
CAS:Amdizalisib is a PI3K inhibitor and used for the research of inflammatory disease, autoimmune disease or cancer.Fórmula:C19H15ClN8Forma y color:SolidPeso molecular:390.84740 Y-P(TFA)
<p>740 Y-P(TFA)(1236188-16-1 free base) (740YPDGFR(TFA)) is a potent and cell-permeable activator of PI3K.</p>Fórmula:C143H223F3N43O41PS3Pureza:98%Forma y color:SolidPeso molecular:3384.73GSK3-IN-1
CAS:<p>GSK3-IN-1 is a GSK3B-glycogen synthase kinase-3 beta inhibitor.</p>Fórmula:C14H10ClN3OSPureza:99.66%Forma y color:SolidPeso molecular:303.77Duligotuzumab
CAS:Duligotuzumab is a dual-targeting anti-EGFR/HER3 mAb that blocks signaling and induces ADCC for tumors with poor prognosis.Pureza:97.7% (SDS-PAGE); 96.3% (SEC-HPLC) - ≥95% (SDS-PAGE); 95.19% (SEC-HPLC)Forma y color:LiquidGSK3-IN-4
CAS:GSK3-IN-4 is a GSK-3 inhibitor with IC50 of 0.101-1 μM of GSK-3α and GSK-3β in Calipe Assay.Fórmula:C18H20N4OPureza:98.33%Forma y color:SoildPeso molecular:308.38Opadotina
Opadotina, a small-molecule anvatabart opadotin, exhibits antineoplastic activity [1].Forma y color:Odour SolidInetetamab
Inetetamab is a recombinant humanized antibody targeting HER2 receptor domain IV, with anticancer activity, inducing pyroptosis in lung adenocarcinoma.Pureza:96.54% (SEC-HPLC) - 96.54% (SEC-HPLC)Forma y color:Odour LiquidPF-06465603
CAS:<p>PF-06465603 is a metabolite of PF-04691502, a highly potent and selective ATP competitive kinase inhibitor of class 1 PI3Ks and mTOR.</p>Fórmula:C22H25N5O5Forma y color:SolidPeso molecular:439.46PROTAC EGFR degrader 3
CAS:Potent PROTAC EGFR degrader 3; excellent against H1975/HCC827 cells; lysosome-involved mutant degradation.Fórmula:C60H77N13O5SForma y color:SolidPeso molecular:1092.4MTX-241F
MTX-241F, a selective small molecule inhibitor, targets members of the EGFR and PI3 kinase families.Fórmula:C20H14ClFN6Pureza:98%Forma y color:SolidPeso molecular:392.82Gefitinib N-oxide hydrochloride
Gefitinib N-oxide hydrochloride is an N-oxide of EGFR inhibitor Gefitinib with IC50 of 2-37 nM.Fórmula:C22H24ClFN4O41·5HClForma y color:SolidPeso molecular:517.59Cetuximab (PBS)
Cetuximab (PBS) is a human IgG1 monoclonal antibody that inhibits the epidermal growth factor receptor (EGFR), with a dissociation constant (Kd) of 0.201 nM for EGFR as measured by the SPR method. It exhibits potent antitumor activity.Forma y color:Odour LiquidCYH33
CAS:<p>CYH33: Oral PI3Kα inhibitor, IC50=5.9 nMα/598 nMβ/78.7 nMδ/225 nMγ; blocks Akt, ERK; causes G1 arrest in breast/lung cancer; effective on solid tumors.</p>Fórmula:C24H29F3N8O5SForma y color:SolidPeso molecular:598.6GSK-3β inhibitor 1
CAS:GSK-3β inhibitor 1 is an inhibitor of GSK-3β( IC50 of 4.9 nM) and demonstrates high antidiabetic efficacy.Fórmula:C14H10N2OPureza:99.40%Forma y color:SolidPeso molecular:222.24PI3Kδ-IN-8
CAS:PI3Kδ-IN-8 is a powerful and specific oral inhibitor of PI3Kδ, exhibiting an IC50 of 3.3 nM.Fórmula:C28H21F2N7OForma y color:SolidPeso molecular:509.521FD274
CAS:<p>FD274 is a potent dual PI3K/mTOR inhibitor with inhibitory effects on PI3Kα/β/γ/δ and mTOR, with IC50s of 0.65 nM, 1.57 nM, 0.65 nM, 0.42 nM, and 2.03 nM,</p>Fórmula:C22H14ClFN6O2SPureza:98%Forma y color:SoildPeso molecular:480.9Depatuxizumab MMAF
<p>Depatuxizumab-MMAF, an antibody-drug conjugate (ADC), comprises an EGFR-targeted antibody linked to McMMAF and is utilized in glioblastoma research.</p>Forma y color:LiquidPeso molecular:148.24 kDa2B-(SP)
CAS:Selective phosphopeptide substrate for glycogen synthase kinase-3 (GSK-3)Fórmula:C71H123N26O29PPureza:98%Forma y color:SolidPeso molecular:1835.87GSK3β/mTOR modulator 1
<p>GSK3β/mTOR modulator 1 (derivative 2) is an agent that modulates the GSK3β/mTOR signaling pathway. It is applicable in research related to acute lung injury (ALI) and inflammation.</p>Fórmula:C19H28O5Forma y color:SolidPeso molecular:336.19367EGFR-IN-79
EGFR-IN-79 (compound 21), an EGFR inhibitor, exhibits antitumor activity through ROS-independent apoptosis and EGFR/AKT/mTOR-mediated autophagy.Fórmula:C23H16ClN3O3Pureza:98%Forma y color:SolidPeso molecular:417.84PI3K-IN-57
<p>PI3K-IN-57 (Compound 4a) is a PI3K inhibitor that shows strong inhibitory effects on the proliferation of HeLa tumor ectopic xenografts in vivo. It holds promise for anticancer agent research.</p>Forma y color:Odour SolidEGFR-IN-116
EGFR-IN-116 (compound 14D) is an antineoplastic agent. It exhibits an IC50 value of 0.103 μM for EGFR, 0.069 μM for VEGFR-2, and 19.74 μM for Topo II.Fórmula:C26H22N6O2SPeso molecular:482.1525EGFR-IN-110
<p>EGFR-IN-110 (Compound 6) is a covalent inhibitor of EGFR, demonstrating pIC50 values of 9.2 for the EGFR enzyme and 8.7 for EGFR cells. It exhibits strong efficacy in targeting EGFR and maintains good kinase selectivity.</p>Fórmula:C22H16ClFN4O2Peso molecular:422.09458PI3Kδ-IN-18
<p>Se15, a selective PI3Kδ inhibitor, exhibits potency with an IC50 value of less than 0.1nM and is utilized in autoimmune research [1].</p>Pureza:98%Forma y color:Odour SolidAMA-37
CAS:AMA-37 is a selective, reversible, and ATP-competitive DNA-PK inhibitor.Fórmula:C17H17NO3Pureza:98%Forma y color:SolidPeso molecular:283.32Anti-Phospho-EGFR (Tyr1068) Antibody (3Q245)
Anti-Phospho-EGFR (Tyr1068) Antibody (3Q245) is an antibody targeting Phospho-EGFR (Tyr1068). Anti-Phospho-EGFR (Tyr1068) Antibody (3Q245) can be used in ELISA, WB.Forma y color:Odour LiquidAnti-EGFR Antibody (3B845)
<p>Anti-EGFR Antibody (3B845) is an antibody targeting EGFR. Anti-EGFR Antibody (3B845) can be used in ELISA, WB, IHC.</p>Forma y color:Odour LiquidAnti-Phospho-EGFR (Tyr1092) Antibody (9I899)
Anti-Phospho-EGFR (Tyr1092) Antibody (9I899) is an antibody targeting Phospho-EGFR (Tyr1092). Anti-Phospho-EGFR (Tyr1092) Antibody (9I899) can be used in ELISA, WB.Forma y color:Odour LiquidAnti-EGFR Antibody (9S619)
Anti-EGFR Antibody (9S619) is an antibody targeting EGFR. Anti-EGFR Antibody (9S619) can be used in ELISA, IHC, FCM.Forma y color:Odour LiquidAnti-EGFR Antibody (7X976)
<p>Anti-EGFR Antibody (7X976) is an antibody targeting EGFR. Anti-EGFR Antibody (7X976) can be used in ELISA, WB, IHC, IF, FCM.</p>Forma y color:Odour LiquidOsimertinib dimesylate
CAS:Osimertinib dimesylate is an irreversible and mutant selective EGFR inhibitor (IC50s: 12 and 1 nM against EGFR L858R and EGFR L858R/T790M).Fórmula:C30H41N7O8S2Pureza:98%Forma y color:SolidPeso molecular:691.82PDK1-IN-RS2
CAS:PDK1-IN-RS2, a PIFtide mimic, selectively inhibits PDK1, blocking S6K1 activation (Kd: 9 μM).Fórmula:C15H9ClN2O2S3Pureza:98%Forma y color:SolidPeso molecular:380.89Mavelertinib
CAS:Mavelertinib (PF-06747775) is an EGFR tyrosine kinase (EGFR TKI) inhibitor that inhibits T790M/L858R and can be used to study tumours.Fórmula:C18H22FN9O2Pureza:99.89%Forma y color:SolidPeso molecular:415.42AV-412 free base
CAS:AV-412 free base is an EGFR inhibitor (IC50s: 0.75, 0.79, 0.5, 2.3, 19 nM for EGFR, EGFR(T790M), EGFR(L858R), EGFR(L858R/T790M) and ErbB2).Fórmula:C27H28ClFN6OForma y color:SolidPeso molecular:507Erlotinib-d6
CAS:Erlotinib is a directly acting inhibitor EGFR tyrosine kinase inhibitor with an IC50 of 2 nM for human EGFR. Erlotinib D6 is a deuterium labeled Erlotinib .Fórmula:C22H23N3O4Pureza:98%Forma y color:SolidPeso molecular:399.47Neratinib maleate
CAS:Neratinib maleate is a selective HER2/EGFR inhibitor (IC50: 59/92 nM) used in breast and prostate cancer studies.Fórmula:C34H33ClN6O7Pureza:99.99%Forma y color:SolidPeso molecular:673.11PF-06843195
CAS:<p>PF-06843195 is a potent and selective PI3Kα inhibitor prevents it catalyzing the conversion of PIP2 to PIP3, inhibit the activation of AKT, anti-tumor .</p>Fórmula:C20H25F3N8O4Pureza:98.01%Forma y color:SolidPeso molecular:498.46
